期刊
CLINICAL AND EXPERIMENTAL HYPERTENSION
卷 43, 期 8, 页码 730-741出版社
TAYLOR & FRANCIS INC
DOI: 10.1080/10641963.2021.1950752
关键词
Hyperuricemia; hypertension; gout; selective urate reabsorption inhibitor; URAT1 inhibitor; dotinurad
Dotinurad effectively lowers serum uric acid levels in hypertensive patients with gout or asymptomatic hyperuricemia, especially at a dose of 4 mg, with consistent long-term results. The drug has a high achievement rate of over 80% in reaching the target serum uric acid level of <= 6.0 mg/dL in both short-term and long-term analyses.
Background: Hyperuricemia is a risk factor for the development of hypertension and is comorbid in many hypertensive patients. According to Japanese hypertension management guidelines published in 2019, a target serum uric acid level of <= 6.0 mg/dL is recommended in hypertensive patients with gout or asymptomatic hyperuricemia. Dotinurad is a novel uric acid-lowering drug classified as a selective urate reabsorption inhibitor. A pooled analysis was performed on the uric acid-lowering effect of dotinurad in 222 hypertensive patients with gout or asymptomatic hyperuricemia in four clinical trials (NCT02344862, NCT02416167, NCT03100318, NCT03372200). Moreover, we analyzed the long-term uric acid-lowering effect of dotinurad in 154 hypertensive patients with gout or asymptomatic hyperuricemia (NCT03006445). Results: In the pooled analysis, the percent change in the decrease of serum uric acid with the use of dotinurad was 42.17 +/- 12.42% at a dose of 2 mg and 60.42 +/- 8.03% at a dose of 4 mg; the percentage of patients who achieved a serum uric acid level of <= 6.0 mg/dL was 82.8% and 100.0%. The long-term uric acid-lowering effect of dotinurad showed almost the same results. In this study, the concomitant use of diuretics or angiotensin II receptor blockers affected the uric acid-lowering effect of dotinurad at only a dose of 2 mg in the pooled analysis. Conclusions: In the pooled analysis, dotinurad lowered serum uric acid levels. Dotinurad has an achievement rate of over 80% for serum uric acid level of <= 6.0 mg/dL in both analyses, and will be clinically useful for the management of hyperuricemic states in hypertensive patients.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据